Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Fonseca, Francina ^a,b,c   de la Torre, Rafael ^b,c,d   Díaz, Laura ^a,c   Pastor, Antonio ^c,e   Cuyàs, Elisabet ^c,e   Pizarro, Nieves ^c,e   Khymenets, Olha ^c,d   Farré, Magí ^c,e   Torrens, Marta ^a,c,e  

^a Institut de Neuropsiquiatria i Addiccions   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^d Instituto de Salud Carlos III   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A5; GLYCOPROTEIN P; METHADONE; MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG METABOLISM; DRUG USE; FEMALE; GENE FREQUENCY; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; OPIATE ADDICTION; OUTCOME ASSESSMENT; PHARMACOGENETICS; ALLELE; BLOOD; GENETICS; MIDDLE AGED; URINE;

ADULT; ALLELES; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; OPIOID-RELATED DISORDERS; P-GLYCOPROTEIN;

EID: 79955939841     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019527     Document Type: Article

References (76)

1. Bell J, Burrell T, Indig D, Gilmour S, (2006) Cycling in and out of treatment; participation in methadone treatment in NSW, 1990-2002. Drug Alcohol Depend 81: 55-61.
2. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, et al. (2000) A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 343: 1290-1297.
3. United States General Accounting Office (1990) Methadone maintenance: some treatment programs are not effective; greater federal oversight needed. Report to the chairman, Select Committee on Narcotics Abuse and Control, House of Representatives. GAO/HRD-90-104.
4. Senbanjo R, Wolff K, Marshall EJ, Strang J, (2009) Persistence of heroin use despite methadone treatment: poor coping self-efficacy predicts continued heroin use. Drug Alcohol Rev 28: 608-615.
5. Elkader AK, Brands B, Dunn E, Selby P, Sproule BA, (2009) Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients. J Clin Psychopharmacol 29: 77-81.
6. Perez de los Cobos J, Sinol N, Trujols J, del Rio E, Banuls E, et al. (2007) Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment. Drug Alcohol Depend 89: 190-194.
7. Epstein DH, Schmittner J, Umbricht A, Schroeder JR, Moolchan ET, et al. (2009) Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency. Drug Alcohol Depend 101: 92-100.
8. Farre M, Mas A, Torrens M, Moreno V, Cami J, (2002) Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend 65: 283-290.
9. Maxwell S, Shinderman M, (1999) Optimizing response to methadone maintenance treatment: use of higher-dose methadone. J Psychoactive Drugs 31: 95-102.
10. Wolff K, Hay A, (1992) Methadone concentrations in plasma and their relationship to drug dosage. Clin Chem 38: 438-439.
11. Eap CB, Bourquin M, Martin J, Spagnoli J, Livoti S, et al. (2000) Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. Drug Alcohol Depend 61: 47-54.
12. Torrens M, Castillo C, San L, del Moral E, Gonzalez ML, et al. (1998) Plasma methadone concentrations as an indicator of opioid withdrawal symptoms and heroin use in a methadone maintenance program. Drug Alcohol Depend 52: 193-200.
13. Kristensen K, Christensen CB, Christrup LL, (1995) The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci 56: PL45-50.
14. Crettol S, Deglon JJ, Besson J, Croquette-Krokar M, Hammig R, et al. (2006) ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 80: 668-681.
15. Li Y, Kantelip JP, Gerritsen-van Schieveen P, Davani S, (2008) Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther 12: 109-124.
16. Foster DJ, Somogyi AA, Bochner F, (1999) Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol 47: 403-412.
17. Shiran MR, Lennard MS, Iqbal MZ, Lagundoye O, Seivewright N, et al. (2009) Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol 67: 29-37.
18. Totah RA, Allen KE, Sheffels P, Whittington D, Kharasch ED, (2007) Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther 321: 389-399.
19. Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, et al. (2008) Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 108: 363-374.
20. Wolff K, Rostami-Hodjegan A, Hay AW, Raistrick D, Tucker G, (2000) Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. Addiction 95: 1771-1783.
21. Wojnowski L, (2004) Genetics of the variable expression of CYP3A in humans. Ther Drug Monit 26: 192-199.
22. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, et al. (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11: 773-779.
23. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27: 383-391.
24. Evans WE, McLeod HL, (2003) Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 348: 538-549.
25. Suh JW, Koo BK, Zhang SY, Park KW, Cho JY, et al. (2006) Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 174: 1715-1722.
26. Le Meur Y, Djebli N, Szelag JC, Hoizey G, Toupance O, et al. (2006) CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther 80: 51-60.
27. Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, et al. (1996) Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 9: 365-373.
28. Kharasch ED, Hoffer C, Whittington D, Sheffels P, (2004) Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 76: 250-269.
29. Wang JS, DeVane CL, (2003) Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos 31: 742-747.
30. Begre S, von Bardeleben U, Ladewig D, Jaquet-Rochat S, Cosendai-Savary L, et al. (2002) Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol 22: 211-215.
31. Eap CB, Bertschy G, Powell K, Baumann P, (1997) Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J Clin Psychopharmacol 17: 113-117.
32. Eap CB, Broly F, Mino A, Hammig R, Deglon JJ, et al. (2001) Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J Clin Psychopharmacol 21: 229-234.
33. Zhou SF, (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 48: 761-804.
34. Shiran MR, Chowdry J, Rostami-Hodjegan A, Ellis SW, Lennard MS, et al. (2003) A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol 56: 220-224.
35. Wu D, Otton SV, Sproule BA, Busto U, Inaba T, et al. (1993) Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Pharmacol 35: 30-34.
36. Wang H, Tompkins LM, (2008) CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 9: 598-610.
37. Crettol S, Deglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, et al. (2005) Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 78: 593-604.
38. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, et al. (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11: 399-415.
39. Gerber JG, Rhodes RJ, Gal J, (2004) Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16: 36-44.
40. Crettol S, Digon P, Golay KP, Brawand M, Eap CB, (2007) In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites. Pharmacology 80: 304-311.
41. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, et al. (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 265-269.
42. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97: 3473-3478.
43. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W, (2005) Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15: 693-704.
44. Wang D, Sadee W, (2006) Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1). AAPS J 8: E515-20.
45. Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA, (2006) ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther 80: 682-690.
46. Levran O, O'Hara K, Peles E, Li D, Barral S, et al. (2008) ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet 17: 2219-2227.
47. Haile CN, Kosten TA, Kosten TR, (2008) Pharmacogenetic treatments for drug addiction: alcohol and opiates. Am J Drug Alcohol Abuse 34: 355-381.
48. Hasin D, Samet S, Nunes E, Meydan J, Matseoane K, et al. (2006) Diagnosis of comorbid psychiatric disorders in substance users assessed with the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV. Am J Psychiatry 163: 689-696.
49. Torrens M, Serrano D, Astals M, Perez-Dominguez G, Martin-Santos R, (2004) Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV. Am J Psychiatry 161: 1231-1237.
50. Gonzalez F, Salvador L, Martinez JM, Lopez A, Ruiz I, et al. (2002) Estudio de fiabilidad y validez de la versión española de la entrevista clínica Addiction Severity Index (ASI). In: Iraurgi I, Gonzalez F, editors. Instrumentos de evaluación en drogodependencias Madrid Aula Medica Ediciones pp. 271-308.
51. McLellan AT, Luborsky L, Woody GE, O'Brien CP, (1980) An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis 168: 26-33.
52. Solans A, de la Torre R, Segura J, (1990) Determination of morphine and codeine in urine by gas chromatography-mass spectrometry. J Pharm Biomed Anal 8: 905-909.
53. Kelly T, Doble P, Dawson M, (2003) Chiral separation of methadone, 2-ethylidene- 1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP) by capillary electrophoresis using cyclodextrin derivatives. Electrophoresis 24: 2106-2110.
54. Cuyas E, Olano-Martin E, Khymenets O, Hernandez L, Jofre-Monseny L, et al. (2010) Errors and reproducibility of DNA array-based detection of allelic variants in ADME genes: PHARMAchip. Pharmacogenomics 11: 257-266.
55. Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, et al. (2004) Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 319: 1322-1326.
56. Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, et al. (2007) Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis 45: 1230-1237.
57. Arenaz I, Vicente J, Fanlo A, Vasquez P, Medina JC, et al. (2010) Haplotype structure and allele frequencies of CYP2B6 in Spaniards and Central Americans. Fundam Clin Pharmacol 24: 247-253.
58. Coller JK, Joergensen C, Foster DJ, James H, Gillis D, et al. (2007) Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone. Int J Clin Pharmacol Ther 45: 410-417.
59. Rendic S, (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34: 83-448.
60. Mann A, Miksys S, Lee A, Mash DC, Tyndale RF, (2008) Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment. Neuropharmacology 55: 1147-1155.
61. Elkader AK, Brands B, Selby P, Sproule BA, (2009) Methadone-nicotine interactions in methadone maintenance treatment patients. J Clin Psychopharmacol 29: 231-238.
62. Bunten H, Liang WJ, Pounder D, Seneviratne C, Osselton MD, (2011) CYP2B6 and OPRM1 gene variations predict methadone-related deaths. Addict Biol 16: 142-144.
63. Mitchell TB, Dyer KR, Newcombe D, Salter A, Somogyi AA, et al. (2004) Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure. Br J Clin Pharmacol 58: 609-617.
64. Reynolds KK, Ramey-Hartung B, Jortani SA, (2008) The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy. Clin Lab Med 28: 581-598.
65. Wu WD, Wang Y, Fang YM, Zhou HY, (2009) Polymorphism of the micro-opioid receptor gene (OPRM1 118A>G) affects fentanyl-induced analgesia during anesthesia and recovery. Mol Diagn Ther 13: 331-337.
66. Klepstad P, Rakvag TT, Kaasa S, Holthe M, Dale O, et al. (2004) The 118 A>G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 48: 1232-1239.
67. Crettol S, Besson J, Croquette-Krokar M, Hammig R, Gothuey I, et al. (2008) Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog Neuropsychopharmacol Biol Psychiatry 32: 1722-1727.
68. Doehring A, Hentig N, Graff J, Salamat S, Schmidt M, et al. (2009) Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution. Pharmacogenet Genomics 19: 407-414.
69. Yuferov V, Fussell D, LaForge KS, Nielsen DA, Gordon D, et al. (2004) Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction. Pharmacogenetics 14: 793-804.
70. Bruijnzeel AW, (2009) Kappa-Opioid receptor signaling and brain reward function. Brain Res Rev 62: 127-146.
71. Kreek MJ, Bart G, Lilly C, LaForge KS, Nielsen DA, (2005) Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 57: 1-26.
72. Crettol S, Deglon JJ, Besson J, Croquette-Krokar M, Hammig R, et al. (2008) No influence of ABCB1 haplotypes on methadone dosage requirement. Clin Pharmacol Ther 83: 668-9.
73. Carlson MJ, Gabriel RM, (2001) Patient satisfaction, use of services, and one-year outcomes in publicly funded substance abuse treatment. Psychiatr Serv 52: 1230-1236.
74. Villafranca SW, McKellar JD, Trafton JA, Humphreys K, (2006) Predictors of retention in methadone programs: a signal detection analysis. Drug Alcohol Depend 83: 218-224.
75. Simpson DD, (1981) Treatment for drug abuse. Follow-up outcomes and length of time spent. Arch Gen Psychiatry 38: 875-880.
76. Teesson M, Ross J, Darke S, Lynskey M, Ali R, et al. (2006) One year outcomes for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Depend 83: 174-180.